Humacyte Prices $50 Million Public Offering at $1.05
Regenerative medicine company Humacyte has officially priced its latest public offering, aiming to raise approximately $50 million in gross proceeds. The company set the offering price at $1.05 per share of its common stock. Proceeds from this capital raise are intended to bolster the company’s balance sheet, supporting its ongoing clinical development programs and general corporate operations as it advances its bioengineered tissue technology.